Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2

Trophoblast cell surface antigen 2 (TROP2) has emerged as a potential target for effective Cancer therapy. In this study, we report a novel anti-Trop2 antibody IMB1636, developed using hybridoma technology. It exhibited high affinity and specificity (K_D = 0.483 nM) in binding both antigens and Cancer cells, as well as human tumor tissues. hIMB1636 could induce endocytosis, and enabled targeted delivery to the tumor site with an in vivo retention time of 264 h. The humanized antibody hIMB1636, acquired using CDR grafting, exhibited the potential to directly inhibit Cancer cell proliferation and migration, and to induce ADCC effects. Moreover, hIMB1636 significantly inhibited the growth of MDA-MB-468 xenograft tumors in vivo. Mechanistically, hIMB1636 induced cell cycle arrest and Apoptosis by regulating cyclin-related proteins and the Caspase cascade. In comparison to commercialized sacituzumab, hIMB1636 recognized a conformational epitope instead of a linear one, bound to antigen and Cancer cells with similar binding affinity, induced significantly more potent ADCC effects against Cancer cells, and displayed superior antitumor activities both in vitro and in vivo. The data presented in this study highlights the potential of hIMB1636 as a carrier for the formulation of antibody-based conjugates, or as a promising candidate for Anticancer therapy.

Antitumor activity; Caspase-dependent apoptosis; Humanization; Monoclonal antibody; Trop2.